Levocetirizine modulates lymphocyte activation in patients with allergic rhinitis

Journal of Pharmacological Sciences

Volumn 108, Issue 2, 2008, Pages 149-156

  Mahmoud, Fadia ^a   Arifhodzic, Nirmina ^b   Haines, David ^c   Novotney, Ladislav ^d  

^a Faculty of Allied Health Sciences

^b KUWAIT UNIVERSITY   (Kuwait)

^c Ministry of Public Health Kuwait   (Kuwait)

^d UNIVERSITY OF CONNECTICUT   (United States)

Author keywords

Peripheral blood; Regulatory T cell (Treg); Rhinitis; T cell

Indexed keywords

BETA1 INTEGRIN; HISTAMINE H1 RECEPTOR; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 12 RECEPTOR BETA1; LEVOCETIRIZINE;

ADULT; ALLERGIC RHINITIS; ARTICLE; CD4+ CD25+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; EOSINOPHILIA; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOREGULATION; KUWAIT; LYMPHOCYTE ACTIVATION; MALE; NASAL PRURITUS; NOSE CONGESTION; PHENOTYPE; REGULATORY T LYMPHOCYTE; RHINORRHEA; SNEEZING;

EID: 55549105115     PISSN: 13478613     EISSN: 13478648     Source Type: Journal    
DOI: 10.1254/jphs.08037FP     Document Type: Article

References (42)

1. Walsh GM. Levocetirizine: an update. Curr Med Chem. 2006;13:2711-2715.
2. Bousquet J, Van Cauwenberg P, Khaltaev N, ARIA Workshop Group, World Health Organization. Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol. 2001;108:S147-S334.
3. Simola M, Malmberg H. Nasal histamine reactivity; relationships to skin-test responses, allergen provocation and symptom severity in patients with long-continuing allergic rhinitis. Acta Otolaryngol. 2000;120:67-71.
4. Behbehani N, Arifhodzic N, Al Mousawi M, Marafie S, Ashkanani L, Moussa M, et al. The seasonal variation in allergic rhinitis and its corelation with outdoor allergens in Kuwait. Int Arch Allergy Immunol. 2004;133:164-167.
5. Christodoulopoulos P, Cameron L, Durham S, Hamid Q. Molecular pathology of allergic disease II: upper airway disease. J Allergy Clin Immunol. 2000;105:211-223.
6. Ciprandi G, Cirillo I, Vizzaccaro A, Tosca MA. Levocetirizine improves nasal obstruction and modulates cytokine pattern in patients with seasonal allergic rhinitis: a pilot study. Clin Exp Allergy. 2004;34:958-964.
7. Hair PI, Scott LJ. Levocetirizine: a review of its use in the management of allergic rhinitis and skin allergies. Drugs. 2006;66:973-996.
8. Bousquet J. Requirements for medication commonly used in the treatment of allergic rhinitis. Allergy. 2003;58:192-197.
9. Bachert C, Brostoff J, Scadding GK, Tasman J, Stalla-Bourdillon A, Murrieta M. Mizolastine therapy also has an effect on nasal blockade in perennial allergic rhinoconjunctivitis. Allergy. 1998;53:969-975.
10. Lipworth BJ, Wilson AM, Haggart K, Sims EJ. Differences in vitro H1-receptor antagonist potency with fexofenadine and desloratadine do not determine effects on nasal congestion in seasonal allergic rhinitis. Allergy. 2002;57 Suppl 73:10.
11. Horak F, Stubner UP, Ziegelmayer R, Harris AG. Effect of desloratadine vs. placebo on nasal airflow and subjective measures of nasal obstruction in subjects with grass pollen-induced allergic rhinitis in an allergen-exposure unit. J Allergy Clin Immunol. 2002;109:956-961.
12. Ciprandi G, Cosentino C, Milanese M, Mondino C, Canonica GW. Fexofenadine treatment reduces nasal congestion in perennial allergic rhinitis. Allergy. 2001;56:1068-1070.
13. Agrawal DK. Anti-inflammatory properties of desloratadine. Clin Exp Allergy. 2004;34:1342-1348.
14. Walsg GM. Anti-inflammatory properties of antihistamines: an update. Clin Exp Allergy Rev. 2005;5:21-25.
15. Albanesi C, Pastore S, Fanales-Belasio E, Girolomoni G. Cetirizine and hydrocortisone differentially regulate ICAM-1 expression and chemokine release in cultured human keratinocytes. Clin Exp Allergy. 1998;28:101-109.
16. Hair PI, Scott LJ. Levocetirizine: a review of its use in the management of allergic rhinitis and skin allergies. Drugs. 2006;66:973-996.
17. Devalia JL, De Vos C, Hanotte F, Baltes E. A randomized doubleblind crossover comparison among cetirizine, levocetirizine and UCB 28557 on histamine-induced cutaneous responses in healthy adult volunteers. Allergy. 2001;56:50-57.
18. Wang DY, Hanotte F, De Vos C, Clement P. Effect of cetirizine, levocetirizine and dextrocetirizine on histamine-induced nasal response in healthy adult volunteers. Allergy. 2001;56:339-343.
19. Salmun LM. Antihistamines in late-phase clinical development for allergic disease. Expert Opin Invest Drugs. 2002;11:259-273.
20. Thomson L, Blaylock MG, Sexton DW, Campbell A, Walsh GM. Cetirizine and levocetirizine inhibit eotaxin-induced eosinophil transendothelial migration through human dermal or lung microvascular endothelial cells. Clin Exp Allergy. 2002;32:1187-1192.
21. Lee DK, Bates CE, Currie GP, Lipworth BJ. Comparative in vivo bioactivity of modern H1-antihistamines on AMP challenge in atopic asthma. J Allergy Clin Immunol. 2003;111:337-341.
22. Lee DK, Gardiner M, Haggart K, Fujihara S, Lipworth BJ. Comparative effects of desloratadine, fexofenadine, and levocetirizine on nasal adenosine monophosphate challenge in patients with perennial allergic rhinitis. Clin Exp Allergy. 2004;34:650-653.
23. Hasala H, Janka-Junttila M, Moilanen E, Kankaanranta H. Levocetirizine and cytokine production and apoptosis of human eosinophils. Allergy Asthma Proc. 2007;28:582-589.
24. Dykewicz MS, Fineman S. Diagnosis and management of rhinitis: parameters documents of the joint task force on practice parameters in allergy, asthma and immunology. Ann Allergy Asthma Immunol. 1998;81:1-87.
25. Al Dowaisan A, Fakim N, Khan MR, Arifhodzic N, Panicker R, Hanoon A, et al. Salsola Pollen as a predominant cause of respiratory allergies in Kuwait. Ann Allergy Asthma Immunol. 2004;92:262-267.
26. Akdis M, Blaser K, Akdis CA. T regulatory cells in allergy: novel concepts in the pathogenesis, prevention, and treatment of allergic diseases. J Allergy Clin Immunol. 2005;116:961-968.
27. Zeiser R, Negrin RS. Interleukin-2 receptor downstream events in regulatory T cells: Implications for the choice of immunosuppressive drug therapy. Cell Cycle. 2007;7:458-462.
28. Sindern E, Oreja-Guevara C, Raulf-Heimsoth M, Baur X, Malin JP. A longitudinal study of circulating lymphocyte subsets in the peripheral blood during the acute stage of Guillain-Barre syndrome. J Neurol Sci. 1997;151:29-34.
29. Baxevanis CN, Papadopoulos NG, Katsarou-Katsari A, Papamichail M. Regulation of allergen-specific immune responses by CD4+ CD45R+ cells in patients with allergic contact dermatitis. J Allergy Clin Immunol. 1994;94:917-927.
30. Hellquist HB, Karlsson MG. Nasal memory T lymphocytes capable of producing IL-4 in the allergic reaction. Allergy. 1992;47:334-336.
31. Watanabe K, Kondo N, Fukutomi O, Takami T, Agata H, Orii T. Characterization of infiltrating CD4+ cells in atopic dermatitis using CD45R and CD29 monoclonal antibodies. Ann Allergy. 1994;72:39-44.
32. Ciprandi G, Tosca M, Ricca V, Passalacqu G, Ricct AM, Bagnasco M, et al. Cetirizine treatment of rhinitis in children with pollen allergy: evidence of its antiallergic activity. Clin Exp Allergy. 1997;27:1160-1166.
33. Mincarini M, Cagnoni F, Canonica GW, Cordone G, Sismondini A, Semino C, et al. Quantitative flow cytometric analysis of the effects of cetirizine on the expression of ICAM-1/CD54 on primary cultured nasal cells. Allergy. 2000;55:226-231.
34. Stokes J, Casale TB. Rationale for new treatments aimed at IgE immunomodulation. Ann Allergy Asthma Immunol. 2004;93:212-217.
35. Michel L, Jean-Louis F, Boland S, Pellet C, Dubertret L. Inhibition by levocetirizine of VCAM-1 production in human dermal endothelial cells in vitro. Allergy. 2003;58 Suppl 74:305-309.
36. Le Gros G, Erb K, Harris N, Holloway J, McCoy K, Ronchese F. Immunoregulatory networks in asthma. Clin Exp Allergy. 1998;5:92-96.
37. Hidi R, Timmermans S, Liu E, Schudt C, Dent G, Holgate ST, et al. Phosphodiesterase and cyclic adenosine monophosphate-dependent inhibition of Tlymphocyte chemotaxis. Eur Respir J. 2000;15:342-349.
38. Calabresse C, Nguer MC, Pellegrini O, Benveniste J, Richard J, Thomas Y. Induction of high-affinity paf receptor expression during T cell activation. Eur J Immunol. 1992;22:1349-1355.
39. Munakata Y, Umezawa Y, Iwata S, Dong RP, Yoshida S, Ishii T, et al. Specific inhibition of TH2-type cytokine production from human peripheral T cells by terfenadine in vitro. Clin Exp Allergy. 1999;29:1281-1286.
40. Seddon B, Mason D. The third function of the thymus. Immunol Today. 2000;21:95-99.
41. Itoh M, Kuniyasu Y, Nomura T, Toda M, Takahashi T. Immunologic tolerance maintained by CD25RCD4Rregulatory T cells: their common role in controlling autoimmunity, tumor immunity, and transplantation tolerance. Immunol Rev. 2001;182:18-32.
42. Morgan RK, McAllister B, Cross L, Green DS, Kornfeld H, Center DM, et al. Histamine 4 receptor activation induces recruitment of FoxP3+ T cells and inhibits allergic asthma in a murine model. J Immunol. 2007;178:8081-8089.